Guggenheim initiated coverage on shares of Zoetis (NYSE:ZTS) in a report issued on Thursday, Briefing.com Automated Import reports. The firm issued a buy rating and a $114.00 target price on the stock.
ZTS has been the topic of several other research reports. Zacks Investment Research lowered shares of Zoetis from a hold rating to a sell rating in a research report on Monday, February 4th. Stifel Nicolaus upgraded shares of Zoetis from a hold rating to a buy rating and lifted their price target for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. SunTrust Banks initiated coverage on shares of Zoetis in a research report on Tuesday, March 19th. They issued a hold rating and a $100.00 price target on the stock. UBS Group started coverage on shares of Zoetis in a research report on Wednesday, January 23rd. They issued a neutral rating and a $86.00 price target on the stock. Finally, BMO Capital Markets lifted their price objective on shares of Zoetis from $101.00 to $105.00 and gave the stock a market perform rating in a research report on Thursday, May 9th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $103.93.
Zoetis stock opened at $102.40 on Thursday. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84. The company has a market capitalization of $49.01 billion, a price-to-earnings ratio of 32.72, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91. Zoetis has a 1 year low of $78.90 and a 1 year high of $104.41.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be given a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.64%. The ex-dividend date is Thursday, July 18th. Zoetis’s payout ratio is 21.09%.
In other news, insider Roman Trawicki sold 17,873 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $95.10, for a total transaction of $1,699,722.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Juan Ramon Alaix sold 312,109 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total transaction of $29,356,972.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 447,975 shares of company stock worth $42,728,902. Corporate insiders own 0.29% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Zoetis by 2.2% during the 1st quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after acquiring an additional 795,558 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of Zoetis by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after acquiring an additional 293,614 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Zoetis by 9,042.7% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after acquiring an additional 14,178,765 shares in the last quarter. Morgan Stanley grew its holdings in shares of Zoetis by 0.9% during the 1st quarter. Morgan Stanley now owns 13,785,853 shares of the company’s stock valued at $1,387,822,000 after acquiring an additional 127,988 shares in the last quarter. Finally, Polen Capital Management LLC grew its holdings in shares of Zoetis by 1.9% during the 4th quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock valued at $817,212,000 after acquiring an additional 178,893 shares in the last quarter. Institutional investors and hedge funds own 90.95% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Bear Market
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.